Objective: To determine if myostatin deficiency attenuates body fat gain with increased dietary fat intake. Methods: Normal and myostatin-deficient mice were fed control (8-10 kcal %fat) and high-fat (HF) (45 kcal %fat) diets for a period of 8 weeks, starting at 2 months of age. Body composition, including percent body fat, lean mass, and fat mass, were measured using DXA. Serum adipokines were measured using a Beadlyte assay. Results: Two-factor ANOVA revealed significant treatment Â genotype interactions for body fat (g), percent body fat, and serum leptin. The HF diet significantly increased body fat, percent body fat, and serum leptin in normal mice but not in myostatindeficient mice. Conclusion: Loss of myostatin function not only increases muscle mass in animal models but also attenuates the body fat accumulation that usually accompanies an HF diet.
Introduction
Myostatin, a member of the transforming growth factor-b superfamily of secreted growth and differentiation factors, is a 52 kDa protein that is expressed in vertebrate skeletal muscle. Whole-embryo in situ hybridization shows that myostatin is first expressed in mouse embryos in the myotome compartment of somites, and myostatin transcripts can still be detected in adult skeletal muscle. 1, 2 Myostatin is a negative regulator of skeletal muscle growth, and myostatin null mice have approximately twice the skeletal muscle mass of normal mice. 1 Studies of mice lacking myostatin indicate that myostatin knockout mice do not accumulate as much body fat during growth and maturation as normal mice, so that 'double-muscled' adult knockout mice tend to be similar in mass to normal adult mice. 3, 4 The lean phenotype of the myostatin-deficient mice suggested to us that these mice might be resistant to dietinduced accumulation of body fat. Resistance to body fat gain in myostatin-deficient mice has potential clinical significance, as myostatin inhibitors may serve as novel pharmacological agents for the prevention and treatment of obesity. 3 We tested this hypothesis in female myostatindeficient mice and wild-type (WT) controls (CONs) over a period of 8 weeks.
Methods
We examined the effects of diet-induced obesity on the accumulation of body fat in myostatin-deficient (KO, CD-1 background) mice by feeding normal (WT; wild-type CD-1/ ICR) mice and myostatin-deficient mice a high-fat (HF; 45 kcal %fat; Research Diets Inc. ) diet for 8 weeks starting at 2 months of age. CON mice of each genotype were fed standard chow (8-10 kcal %fat; Harlan TekLad Rodent Chow). It is known that chow diets may vary from batch to batch, more so than defined diets, and so slight variation in diet composition, apart from fat content, may also differ between the two groups. Mice were killed by CO 2 overdose as approved by the Medical College of Georgia (protocol #05-03-479). Lean and fat mass, percent body fat, bone mineral content (BMC), and bone mineral density (BMD) were analyzed using DXA (PIXImus system, software version 1.4 Â ). Blood was collected by cardiac puncture and serum leptin and resistin levels measured using a Luminex assay kit (Linco Research). Single-factor ANOVA was used to test for significant differences between treatment groups (n ¼ 12 per group) and Fishers LSD test used for post hoc pairwise comparisons. Two-factor ANOVA with diet (HF or CON) and genotype (WT or KO) as the two factors was used to test for significant genotype Â diet interaction effects.
Results
Single-factor ANOVA results indicate significant betweengroup differences for body fat mass, percent body fat, and lean mass (Table 1) . Mean values for each treatment group show that whereas fat mass and percent body fat increased by 70-80% in WT mice fed an HF diet, these parameters increased by less than 25% in the myostatin-deficient mice fed an HF diet (Table 1 ). Lean mass decreased by 10% in WT mice on the HF diet compared to mice on the control diet, whereas lean mass decreased by only 5% in the myostatindeficient mice on the HF diet compared to knockout mice on the control diet (Table 1) . Serum adipokines show a similar pattern, in which serum leptin and resistin levels increased significantly in normal mice on the HF diet but not in myostatin-deficient mice on the HF diet (Table 2) . Two-factor ANOVA revealed significant (Po0.05) treatment Â genotype interactions for four variables: fat mass, percent body fat, serum leptin, and BMC. Raw data show that these different interaction effects result from the fact that fat mass, percent body fat, and serum leptin increased much more in the WT mice on the HF diet, whereas body fat accumulation was attenuated in myostatin-deficient mice on the HF diet. BMC actually decreased with increased dietary fat in the WT mice, whereas BMC increased slightly in the myostatin-deficient mice.
Discussion
Myostatin-deficient mice have previously been shown to have reduced body fat, and genetic crosses of myostatindeficient mice with leptin-deficient ob/ob mice partially inhibited body fat accumulation and the abnormal glucose metabolism characteristic of the ob/ob mouse model. 3 More recently, a child with a naturally occurring mutation in the myostatin gene was also shown to have increased muscle mass as well as decreased subcutaneous fat. 5 In another study, weight loss in morbidly obese subjects was associated with significant downregulation of myostatin mRNA in muscle biopsies, suggesting a role for myostatin in energy partitioning between protein and fat. 6 Several possible mechanisms have been proposed to explain these findings, including a direct effect of myostatin on adipocyte differentiation and maturation. In vitro studies have shown that myostatin can inhibit adipocyte differentiation in 3T3-L1 mouse preadipocytes, 7 and myostatin may also inhibit Reduced body fat gain in double-muscled Mice MW Hamrick et al BMP-7 mediated adipogenesis by binding to the same receptor as BMP-7, the activin IIB receptor. 8 These data suggest that loss of myostatin function should increase adipogenesis, but the in vivo data obviously do not support this prediction. Alternatively, myostatin has been observed to promote adipogenesis in multipotential mesenchymal cells, suggesting that loss of myostatin function may directly suppress adipocyte differentiation. 9 Our results are consistent with these in vitro findings; however, it is also known that other mouse models showing increased muscle mass, such as transgenic mice overexpressing IGF-1, 10,11 Akt, 12 and ski 13 show decreased fat mass. It is therefore possible that an indirect effect of double-muscling on fat metabolism may also be involved in the resistance to body fat accumulation in the myostatin-deficient animals; however, indirect calorimetry studies have found no significant differences in the respiratory exchange ratio between normal mice and myostatin-deficient rodents. 3 Nevertheless, our results indicate that loss of myostatin function attenuates body fat gain induced by an HF diet, in addition to inhibiting the accumulation of body fat in genetic models obesity. These data, in addition to the fact that subcutaneous fat is reduced in humans lacking myostatin, provide further support for the idea that pharmacological blockade of myostatin function may be useful for the prevention of body fat gain in humans.
